Brixadi (Buprenorphine) Patent Expiration, LOE Window & CMS Spending
Brixadi (Buprenorphine) by Braeburn: FDA Orange Book LOE 2032-07-26, 12 AB generics, $126.4M 2024 CMS Part D & Medicaid spend, and $1,595 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Braeburn |
| FDA Application & Pathway | N210136 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2032-07-26 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $126.4M |
| 2024 Medicare Part D Spend | $11.2M |
| 2024 Medicaid Spend | $115.2M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,595 intro WAC) |